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BACKGROUND
Postlicensure evaluations have identified an association between rotavirus vaccina-
tion and intussusception in several high- and middle-income countries. We assessed 
the association between monovalent human rotavirus vaccine and intussusception 
in lower-income sub-Saharan African countries.
METHODS
Using active surveillance, we enrolled patients from seven countries (Ethiopia, 
Ghana, Kenya, Malawi, Tanzania, Zambia, and Zimbabwe) who had intussuscep-
tion that met international (Brighton Collaboration level 1) criteria. Rotavirus 
vaccination status was confirmed by review of the vaccine card or clinic records. 
The risk of intussusception within 1 to 7 days and 8 to 21 days after vaccination 
among infants 28 to 245 days of age was assessed by means of the self-controlled 
case-series method.
RESULTS
Data on 717 infants who had intussusception and confirmed vaccination status were 
analyzed. One case occurred in the 1 to 7 days after dose 1, and 6 cases occurred 
in the 8 to 21 days after dose 1. Five cases and 16 cases occurred in the 1 to 7 days 
and 8 to 21 days, respectively, after dose 2. The risk of intussusception in the 1 to 
7 days after dose 1 was not higher than the background risk of intussusception 
(relative incidence [i.e., the incidence during the risk window vs. all other times], 
0.25; 95% confidence interval [CI], <0.001 to 1.16); findings were similar for the 
1 to 7 days after dose 2 (relative incidence, 0.76; 95% CI, 0.16 to 1.87). In addition, 
the risk of intussusception in the 8 to 21 days or 1 to 21 days after either dose was 
not found to be higher than the background risk.
CONCLUSIONS
The risk of intussusception after administration of monovalent human rotavirus 
vaccine was not higher than the background risk of intussusception in seven 
lower-income sub-Saharan African countries. (Funded by the GAVI Alliance through 
the CDC Foundation.)
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Intussusception is a rare event that occurs when one segment of the bowel tele-scopes into another, which results in ob-
struction. A previously licensed rotavirus vaccine 
(RotaShield, Wyeth-Lederle Laboratories) was 
found to be associated with intussusception af-
ter its introduction in the routine immunization 
program in the United States.1 It has been esti-
mated that 1 excess case of intussusception per 
10,000 infants vaccinated with RotaShield oc-
curred in the United States.1,2 This vaccine was 
subsequently withdrawn from use.
On the basis of this finding, the World Health 
Organization (WHO) recommended that intus-
susception be carefully monitored during the 
clinical trials of the newer rotavirus vaccines, the 
monovalent Rotarix vaccine (RV1, GlaxoSmith-
Kline) and pentavalent RotaTeq vaccine (RV5, 
Merck). Prelicensure clinical trials (involving 
approximately 60,000 to 70,000 infants each) of 
RV1 or RV5 did not find an association with in-
tussusception.3,4 However, postmarketing surveil-
lance detected an increased risk of intussuscep-
tion, of approximately 1 to 6 excess cases per 
100,000 vaccinated children, in association with 
both RV1 and RV5 in several high- and middle-
income countries, including Australia, Mexico, 
Brazil, the United States, Singapore, and the 
United Kingdom.5-10 The risk was seen primarily 
in the first week after receipt of the first dose of 
rotavirus vaccine, although an increased risk has 
been observed after the second dose in some 
countries.5,8,10 The WHO Global Advisory Com-
mittee on Vaccine Safety, which continually re-
views data on vaccines in current use, has evalu-
ated the data available to date and reaffirmed its 
recommendation for use of the vaccine, recog-
nizing that the real-world benefits of rotavirus 
vaccination, including documented declines in 
childhood mortality and hospitalizations related 
to diarrhea, outweigh the short-term smaller risk 
of intussusception.11
By June 2017, a total of 32 countries in sub-
Saharan Africa, where more than half of all 
deaths due to rotavirus occur, had introduced 
rotavirus vaccine into their national immuniza-
tion programs.12 Data from large-scale safety 
assessments of the rotavirus vaccine conducted 
in low-income countries, including those in Af-
rica, are lacking, and only sparse data regarding 
the incidence of intussusception in the region are 
available.13 The available data indicate that the 
diagnosis and treatment of intussusception in 
Africa is markedly different from that reported 
in other regions, and the disease is often associ-
ated with higher fatality rates in Africa, probably 
because of less access and late presentation to 
medical care.14 Furthermore, the efficacy and 
effectiveness of rotavirus vaccines are lower in 
low-income countries than in middle- and high-
income countries.15-18 Thus, it may not be valid to 
extrapolate the findings from studies of the asso-
ciation between rotavirus vaccine and intussus-
ception that have been performed in middle- and 
high-income countries to low-income settings, 
given the differences in diagnosis, treatment, and 
outcome of intussusception between these settings.
To assess whether there is any association 
between RV1 vaccination and intussusception 
after introduction of the vaccine into the routine 
childhood immunization schedule in African 
countries, the African Intussusception Surveil-
lance Network was established in seven low- and 
low-middle-income sub-Saharan African coun-
tries that were early adopters of RV1.
Me thods
Study Design
To monitor the safety of the rotavirus vaccines 
that are in use in national immunization pro-
grams, intussusception surveillance was estab-
lished at sentinel hospitals in seven countries 
that were early adopters of RV1 in sub-Saharan 
Africa (Ethiopia, Ghana, Kenya, Malawi, Tanzania, 
Zambia, and Zimbabwe). Countries joined the 
network on a rolling basis after the introduction 
of RV1 into their routine childhood immuniza-
tion programs. Surveillance began in the first 
country in February 2012 and ended in all coun-
tries in December 2016. Participating countries 
used a common surveillance protocol to allow 
for pooling of data across sites and countries. 
Site investigators conducted active surveillance 
to identify cases of intussusception at major 
pediatric hospitals that were located in large 
urban areas of the participating countries. In-
fants younger than 12 months of age whose 
condition met the Brighton Collaboration crite-
ria for level 1 of diagnostic certainty for intus-
susception were enrolled, regardless of RV1 vac-
cination status. Level 1 of diagnostic certainty 
requires confirmation of intussusception during 
surgery, by specific radiologic findings (if reduc-
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tion occurred as a result of an enema), or at 
autopsy.19
Limited clinical and sociodemographic data 
were collected in interviews with the parents or 
guardians and by review of the infant’s medical 
record. The onset of intussusception was de-
fined as the date of the first symptoms reported 
by the parent or guardian. Vaccination status 
and dates were obtained from vaccination cards 
that were brought to the hospital or, if the vac-
cine card was unavailable, by visiting the infant’s 
home or the clinic where the infant was vacci-
nated. For most cases, a photocopy or photo-
graph of the vaccine card or clinic record was 
made for future reference and for confirmation 
of vaccination status. In all participating coun-
tries, two doses of RV1 were recommended to be 
given at the first two Expanded Program on Im-
munization (EPI) visits, at 6 and 10 weeks of age, 
along with the other EPI vaccines, including the 
oral polio vaccine. Additional doses of rotavirus 
vaccine were contraindicated if an infant had an 
episode of intussusception before completion of 
the vaccine series. For case patients whose intus-
susception was diagnosed before 8 months of age, 
efforts were made to recontact their families 
when the infant reached 8 months of age to 
determine whether the infant had received any 
additional doses of rotavirus vaccine or had had 
a recurrent episode of intussusception and to 
assess the vital status of the infant.
The authors vouch for the completeness and 
accuracy of the data and analysis presented. This 
evaluation was determined to be public health 
nonresearch during the Centers for Disease Con-
trol and Prevention human subjects review, and 
the WHO Research Ethics Review Committee 
granted an exemption, noting that the proce-
dures involved in the study are part of routine 
hospital-based surveillance.
Statistical Analysis
The resource-efficient and validated self-con-
trolled case-series method was applied to assess 
intussusception risk after RV1 administration.8,10,20 
This method relies on the identification of intus-
susception cases and on linking each record with 
the vaccination status of the patient. Since each 
case acts as its own control for time-invariant 
confounders in this method, no external con-
trols or population-level vaccination data were 
required for the assessment of risk. We used an 
adaptation of the self-controlled case-series 
method (the pseudo-likelihood method) that al-
lowed for contraindication of rotavirus vaccina-
tion after an episode of intussusception.21
Given the findings from previous analyses of 
RV1 and intussusception, we hypothesized that 
the risk of intussusception would be highest in 
the 1 to 7 days after vaccination (with vaccination 
occurring on day 0), which corresponds to the 
period during which peak intestinal replication 
of the RV1 vaccine virus is thought to occur.22 
We also examined risk periods of 8 to 21 days 
and 1 to 21 days after each dose of RV1. Given 
the timing of rotavirus vaccine administration, 
we limited the analysis to infants who were 28 to 
245 days of age at the time of intussusception 
onset. To account for the varying underlying age 
distribution of patients with intussusception, we 
controlled for age in the model using 14-day age 
bands. Infants who were not age-eligible for RV1 
vaccination (e.g., infants who had been born 
several months before vaccine introduction) and 
infants who were age-eligible but did not receive 
RV1 were also included in the model to provide 
stability to the underlying age distribution. Rela-
tive incidence and confidence intervals were cal-
culated with the use of conditional Poisson re-
gression comparing the incidence within the risk 
window with the incidence in all other observa-
tion windows for each infant. Confidence inter-
vals were derived by bootstrapping with 1000 
iterations.
We estimated that 400 cases of intussuscep-
tion would provide 80% power to detect a rela-
tive incidence of 2.5 or more within 1 to 7 days 
after the first dose of RV1, under the assumption 
of 70% vaccine coverage and a type 1 alpha level 
of 0.05. Data were analyzed with the use of Stata 
software, version 14 (StataCorp), and SAS soft-
ware, version 9.4 (SAS Institute).
R esult s
Characteristics of the Patients
A total of 1060 infants who were younger than 
12 months of age and had intussusception were 
enrolled in surveillance from 29 sentinel hospi-
tals located in seven countries (Table 1). Of these 
infants, 239 were excluded from the analysis be-
cause they were younger than 28 days of age or 
older than 245 days of age at the time of intus-
susception symptom onset, and an additional 
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104 infants were excluded because their vaccina-
tion status could not be confirmed, which result-
ed in 717 infants being included in the analysis. 
Ghana, the first country in the network to intro-
duce the rotavirus vaccine, had the largest num-
ber of patients in the analysis (258 infants [36%]).
The median age of the infants included in the 
analysis was 25 weeks, with few cases of intus-
susception detected in very young infants 4 to 11 
weeks of age (Fig. 1); 61% of the infants (436 of 
717) were male. Among the infants for whom 
information was available, only 2% (10 of 664) 
had never received any breast milk before the 
onset of intussusception, 68% (438 of 644) lived 
in a household in which at least one person was 
employed, 73% (455 of 627) lived in a household 
that had electricity at least part of the time, and 
80% (522 of 650) lived in a household with a 
mobile telephone.
Clinical Features of Intussusception  
and Vaccination Coverage
The median duration between symptom onset and 
admission to a surveillance facility was 3 days 
(interquartile range, 1 to 4), with 78% of the 
infants (420 of 537) first seeking care at another 
facility. The majority of the infants were treated 
surgically (87% [615 of 704]), with 57% of these 
infants (353 of 615) undergoing resection of the 
bowel; 13% (89 of 704) were treated with an 
enema. Overall, 12% (80 of 681) of the patients 
with intussusception died.
Vaccination coverage was high, and receipt of 
the vaccine was timely (Fig. 1). A total of 10% of 
the patients with intussusception who were in-
Country
Month and Year of 
Vaccine Introduction Enrollment Period
Sentinel 
Hospitals 
(N = 29)
Patients <12 Mo of Age 
with Intussusception 
(N = 1060)
Patients 28–245 Days of Age 
with Intussusception and 
Confirmed Vaccination 
(N = 717)
no. no. of patients (%)
Ethiopia November 2013 December 2013– 
December 2016
6 164 (15) 80 (11)
Ghana April 2012 February 2012– 
December 2016
2 381 (36) 258 (36)
Kenya July 2014 October 2014– 
December 2016
5 135 (13) 97 (14)
Malawi October 2012 November 2013– 
November 2016
4 28 (3) 23 (3)
Tanzania January 2013 January 2013– 
December 2016
7 201 (19) 144 (20)
Zambia January 2012* August 2013– 
November 2016
4 61 (6) 47 (7)
Zimbabwe May 2014 August 2014– 
December 2016
1 90 (8) 68 (9)
*  The vaccine was introduced in Lusaka Province as part of a demonstration project in January 2012 and was introduced nationwide in 
November 2013.
Table 1. Rotavirus Vaccine Introduction, Enrollment Periods, and Numbers of Patients with Intussusception Enrolled According to Country, 
February 2012 through December 2016.
Figure 1. Ages at Immunization and at Onset of Intussusception, February 
2012 through December 2016.
Gray bars indicate the numbers of intussusception cases according to age 
at symptom onset, and the blue and orange lines indicate the numbers of 
doses of rotavirus vaccine administered according to age at immunization.
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cluded in the analysis were unvaccinated, 6% had 
received only one dose of RV1, and 84% had re-
ceived two doses of RV1. The median age at dose 
1 was 6 weeks (interquartile range, 6 to 7), and 
the median age at dose 2 was 11 weeks (inter-
quartile range, 10 to 12). Despite the contraindi-
cation, 5 infants received at least one dose of 
RV1 after intussusception. The families of 445 
(70%) of the 637 surviving infants were recon-
tacted when the infants were 8 months of age; 
14 infants (3%) had had a second episode of in-
tussusception, and 7 (2%) had died after hospital 
discharge and before reaching 8 months of age.
Evaluation of Intussusception Risk  
after Vaccination
No clustering of cases occurred in any of the risk 
windows (1 to 7 days, 8 to 21 days, or 1 to 21 
days) after receipt of either dose of RV1 (Fig. 2). 
One case occurred in the 1 to 7 days after dose 
1, and 6 cases occurred in the 8 to 21 days after 
dose 1. Five cases occurred in the 1 to 7 days 
after dose 2, and 16 occurred in the 8 to 21 days 
after dose 2 (Table 2). The risk of intussuscep-
tion in the 1 to 7 days after dose 1 was not 
higher than the background risk (relative inci-
dence, 0.25; 95% confidence interval [CI], <0.001 
to 1.16); findings were similar for the 1 to 7 days 
after dose 2 (relative incidence, 0.76; 95% CI, 
0.16 to 1.87). In addition, the risk of intussus-
ception in the 8 to 21 days or 1 to 21 days after 
either dose was not higher than the background 
risk (Table 2).
Discussion
In our study in low- and low-middle-income 
countries in sub-Saharan Africa, the risk of 
Figure 2. Cases of Intussusception after Dose 1 and Dose 2 of the Rotavirus Vaccine, February 2012 through December 2016.
Shown are the distributions of cases of intussusception during the 60 days after the first and second doses of monovalent rotavirus vaccine. 
An additional 589 cases occurred more than 60 days after dose 1, and an additional 460 cases occurred more than 60 days after dose 2.
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intussusception in association with RV1 vaccina-
tion was not higher than the background risk. 
This finding contrasts with previous studies in 
high- and upper-middle-income countries, in which 
an association with intussusception was found. 
There are several possible explanations for this 
difference in risk according to setting. First, al-
though the exact mechanism is not known, intus-
susception may be related to intestinal replica-
tion of the orally administered, live vaccine 
rotavirus strain. Because oral rotavirus vaccines 
are less efficacious and shedding of vaccine virus 
— a potential marker of vaccine replication — is 
less frequently detected in low-income countries 
than in high- and middle-income countries,15,17 
rotavirus vaccination might also be associated 
with a lower intussusception risk in low-income 
countries. Second, rotavirus vaccine is coadmin-
istered with oral polio vaccine in low-income 
countries, and the first dose of oral polio vac-
cine, which is associated with the greatest repli-
cation of the vaccine poliovirus, has been shown 
to decrease the immunogenicity of the first dose 
of RV1 when coadministered.23 This phenomenon 
was considered as a potential reason for the 
absence of an increased risk of intussusception 
after the first dose of RV1 in Brazil, the other 
country in which no such association was ob-
served after dose 1.10 However, in Brazil, a low-
level association between RV1 vaccination and 
intussusception was found after the second 
dose.10 Third, the two doses of RV1 were ad-
ministered at younger ages (6 and 10 weeks) in 
these low-income African countries than in high- 
and middle-income countries (generally 2 and 
4 months). Because intussusception is uncommon 
in the first 2 months of life, RV1 administration 
at these young ages might not be associated with 
intussusception in African countries, especially 
if the causes of intussusception differ between 
younger infants and older infants. Finally, other 
factors that may play a role in the risk of intus-
susception in younger infants and that differ 
between these low-income African countries and 
high- and middle-income countries (e.g., diet, 
breast-feeding practices, microbiome, or levels of 
maternal antibodies) might, through unknown 
mechanisms, also partially account for the dif-
ferences in the risk of intussusception after RV1 
vaccination.
Given the higher background rate of intus-
susception among older infants, the initial WHO 
recommendations that were issued in 2009 speci-
fied that the rotavirus vaccine series be initiated 
by 15 weeks of age to avoid amplifying any poten-
tial vaccine-associated risk of intussusception.24 
However, because of the recognition that many 
infants could be excluded from receiving rota-
virus vaccine under these age restrictions, espe-
cially in some low-income, high-burden countries 
where delays in vaccination are more common, 
these age restrictions were reviewed. A modeling 
study in which data on vaccine efficacy from 
clinical trials and the available data on the risk 
of intussusception after vaccination from post-
licensure evaluations in middle- and high-income 
countries were analyzed showed that removing 
these age restrictions would avert 154 deaths 
from rotavirus infection for every death from 
vaccine-related intussusception in low-income 
countries.25 On the basis of these data, in Janu-
ary 2013, the WHO recommended removal of 
the age restrictions for rotavirus vaccines in order 
to improve vaccine coverage. The timely admin-
istration of RV1 in these countries that were 
early adopters of the vaccine, with only 3% of 
infants receiving RV1 after 15 weeks of age, may 
mean that the generalizability of our results to 
countries with substantial delays in vaccine ad-
ministration is limited. If the dynamics of RV1 
replication and immune response differ between 
older infants and younger infants (e.g., if repli-
Dose and Risk 
Period
No. of 
 Cases
Relative Incidence 
 (95% CI)*
Dose 1
Days 1–7 1 0.25 (<0.001–1.16)
Days 8–21 6 1.01 (0.26–2.24)
Days 1–21 7 0.85 (0.35–1.73)
Dose 2
Days 1–7 5 0.76 (0.16–1.87)
Days 8–21 16 0.74 (0.39–1.20)
Days 1–21 21 0.81 (0.49–1.22)
*  Relative incidence is a ratio of the incidence within the 
risk window versus the incidence in all other observation 
windows for each infant, calculated with the use of condi-
tional Poisson regression.
Table 2. Relative Incidence of Intussusception in the Risk 
Periods after the First and Second Doses of Monovalent 
Rotavirus Vaccine, February 2012 through December 2016.
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cation and immune response are greater in older 
children), the risk of intussusception may also 
differ.
Our study had some limitations. First, a lack 
of suspicion of intussusception and delays in 
seeking health care could have resulted in some 
infants dying from intussusception before they 
reached a surveillance facility. Although this 
would have reduced the number of cases identi-
fied, these delays probably would have been in-
dependent of vaccination status and therefore 
probably would not have biased our results. How-
ever, if infants with intussusception who were 
not brought to a health care facility for treat-
ment were more likely to have been vaccinated 
late, then our results may not be generalizable 
to those infants. The age distribution of the 
patients with intussusception in our study was 
similar to that seen in the United States and 
other countries with good access to care,14,26 
with few cases occurring in the first 12 weeks of 
life, which indicated that we were not selectively 
missing cases in younger infants during the 
period when vaccine doses are given. The exact 
reasons for lower rates of intussusception among 
younger infants are not well understood, but 
they may be related to the decline in maternal 
antibodies to pathogens associated with intus-
susception or to age-related milestones in the 
maturation of intestinal lymphoid tissue. If we 
did selectively miss cases among younger in-
fants, then we may have underestimated the true 
risk of intussusception after vaccination.
Second, we used the date of the first symp-
tom reported by the parent as the date of intus-
susception onset, rather than the date of hospi-
tal admission, which has been used in many 
previous analyses. We chose to use the date of 
symptom onset because there was a median of 
3 days between symptom onset and admission to 
the surveillance facility. We were concerned that 
if the admission date were used as the marker 
for the date that intussusception occurred, some 
infants would be excluded from the 1-to-7-day 
risk window. When we used the date of hospital 
admission as the date of onset or a longer risk 
window for the analysis, we still did not see an 
increased risk of intussusception.
Third, the infants and their parents or guard-
ians frequently traveled long distances to reach 
the surveillance facilities, and they often did not 
have their vaccine cards with them. This neces-
sitated great effort by surveillance staff to find 
ways to confirm the vaccination status of the 
enrolled infants. Overall, we were able to con-
firm the vaccination status of 87% of age-eligi-
ble infants, and there was no significant differ-
ence in the age distribution between infants for 
whom we confirmed vaccination status and those 
for whom we did not.
Finally, the presentation and treatment of in-
tussusception in the countries in this evaluation 
differ from those observed in other regions of 
the world in terms of delays in presentation, 
surgery rates, and mortality.14 Although a better 
understanding of these data is important for 
better treatment and outcomes for patients with 
intussusception, such analyses were outside the 
scope of the current evaluation.
The self-controlled case-series approach pro-
vided an efficient method that can be applied in 
resource-limited settings to evaluate the risk of 
intussusception after rotavirus vaccination. Be-
cause intussusception is a rare adverse event and 
a large sample size is required in order to assess 
the risk of this condition developing after rota-
virus vaccination, such evaluations may not be 
feasible and practical in all countries in which 
the rotavirus vaccine is introduced. As this vac-
cine or other rotavirus vaccines in the pipeline 
are introduced into other regions, such as Asia, 
in which evaluations of rotavirus vaccine and 
intussusception have not been performed, and 
given the regional differences in the epidemiol-
ogy of intussusception, similar evaluations will 
be important for an assessment of the regional 
benefits and risks associated with rotavirus vac-
cination. In the 29 African countries that had 
introduced rotavirus vaccine into their national 
immunization program by the end of 2014, ap-
proximately 135,000 hospitalizations and 21,000 
deaths resulting from rotavirus infection were 
estimated to have been prevented in 2016.27 
Given these large health benefits, the absence of 
increased risk of intussusception after RV1 ad-
ministration in our study is reassuring.
The findings and conclusions in this report are those of the 
authors and do not necessarily represent the official position of 
the Centers for Disease Control and Prevention (CDC) or the 
World Health Organization.
Supported by the Gavi Alliance through the CDC Foundation.
Disclosure forms provided by the authors are available with 
the full text of this article at NEJM.org.
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